Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTREPID OLE: Brazikumab in Crohn's Disease
NCT03961815Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Jan 2020
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 3, open-label trial of brazikumab in Crohn's disease (2 arms), sponsored by AstraZeneca. Primary endpoints: Adverse Events at 70 weeks, Laboratory Values at 70 weeks and 2 more. Started Jan 2020; status: terminated.
02
Drugs
brazikumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03961815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03961815.